Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

A month has gone by since the last earnings report for Keros Therapeutics, Inc. (KROS). Shares have added about 8% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Keros Therapeutics due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Keros Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros reported a second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share reported in the year-ago quarter.

Keros recorded no revenues, down 100% from $18.2 million a year earlier.

KROS' Q2 Results in Detail

Keros does not have a marketed product and therefore lacks a regular source of revenues. The company periodically records service and other revenues as well as license revenues, making quarterly comparisons dependent on the timing of collaboration-related revenue recognition.

Service and other revenues were nil in the reported quarter compared with $18.2 million in the prior-year period. License revenues were also nil in both periods.

Research and development expenses declined 48.7% year over year to $22.3 million. The decrease primarily reflected the transfer of elritercept-related development costs to Takeda and the corporate restructuring completed in 2025.

General and administrative expenses fell 40.6% year over year to $8.6 million. The decrease was due to lower professional fees and reduced compensation costs tied to the 2025 restructuring.

KROS’ Cash Runway

Cash and cash equivalents totaled $257.6 million as of June 30, 2026, down from $281.5 million as of March 31, 2026.

Based on current operating assumptions, Keros expects its cash resources to fund operating expenses and capital expenditure requirements into the first half of 2028. The runway supports the ongoing development of rinvatercept as the company advances its clinical programs, with no recurring product revenues.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a flat trend in fresh estimates.

The consensus estimate has shifted 22.12% due to these changes.

VGM Scores

At this time, Keros Therapeutics has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the fifth quintile for value investors.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Keros Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Keros Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Viking Therapeutics, Inc. (VKTX), a stock from the same industry, has gained 2.2%. The company reported its results for the quarter ended June 2026 more than a month ago.

Viking Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$1.10 for the same period compares with -$0.58 a year ago.

For the current quarter, Viking Therapeutics is expected to post a loss of $1.00 per share, indicating a change of -23.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days.

Viking Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research